Corvus Pharmaceuticals price target raised to $13 from $8 at Jefferies
The Fly

Corvus Pharmaceuticals price target raised to $13 from $8 at Jefferies

Jefferies raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $13 from $8 and keeps a Buy rating on the shares ahead of the report of Phase 1 interim data from soquelitinib in atopic dermatitis that is expected in December. The data from first two doses could provide the clinical proof of concept for the oral ITK inhibitor in broader I&I, or inflammation and immunology, the analyst tells investors.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App